Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 03 2021
Historique:
received: 08 09 2020
revised: 14 10 2020
accepted: 16 12 2020
pubmed: 6 2 2021
medline: 10 4 2021
entrez: 5 2 2021
Statut: ppublish

Résumé

To study the characteristics and outcome among cardiac arrest cases with COVID-19 and differences between the pre-pandemic and the pandemic period in out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA). We included all patients reported to the Swedish Registry for Cardiopulmonary Resuscitation from 1 January to 20 July 2020. We defined 16 March 2020 as the start of the pandemic. We assessed overall and 30-day mortality using Cox regression and logistic regression, respectively. We studied 1946 cases of OHCA and 1080 cases of IHCA during the entire period. During the pandemic, 88 (10.0%) of OHCAs and 72 (16.1%) of IHCAs had ongoing COVID-19. With regards to OHCA during the pandemic, the odds ratio for 30-day mortality in COVID-19-positive cases, compared with COVID-19-negative cases, was 3.40 [95% confidence interval (CI) 1.31-11.64]; the corresponding hazard ratio was 1.45 (95% CI 1.13-1.85). Adjusted 30-day survival was 4.7% for patients with COVID-19, 9.8% for patients without COVID-19, and 7.6% in the pre-pandemic period. With regards to IHCA during the pandemic, the odds ratio for COVID-19-positive cases, compared with COVID-19-negative cases, was 2.27 (95% CI 1.27-4.24); the corresponding hazard ratio was 1.48 (95% CI 1.09-2.01). Adjusted 30-day survival was 23.1% in COVID-19-positive cases, 39.5% in patients without COVID-19, and 36.4% in the pre-pandemic period. During the pandemic phase, COVID-19 was involved in at least 10% of all OHCAs and 16% of IHCAs, and, among COVID-19 cases, 30-day mortality was increased 3.4-fold in OHCA and 2.3-fold in IHCA.

Identifiants

pubmed: 33543259
pii: 6128749
doi: 10.1093/eurheartj/ehaa1067
pmc: PMC7928992
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1094-1106

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2010 Jul 29;363(5):434-42
pubmed: 20818864
N Engl J Med. 2020 Jul 30;383(5):496-498
pubmed: 32348640
BMC Bioinformatics. 2008 Jul 11;9:307
pubmed: 18620558
N Engl J Med. 2015 Jun 11;372(24):2307-15
pubmed: 26061835
Resuscitation. 2013 Jul;84(7):952-6
pubmed: 23313425
JAMA Cardiol. 2020 Oct 1;5(10):1154-1163
pubmed: 32558876
Heart. 2020 Dec;106(23):1812-1818
pubmed: 33023905
N Engl J Med. 2020 Jun 11;382(24):2368-2371
pubmed: 32302076
Lancet Public Health. 2020 Aug;5(8):e437-e443
pubmed: 32473113
Resuscitation. 2020 May;150:130-138
pubmed: 32209378
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
J Cardiothorac Vasc Anesth. 2021 Jun;35(6):1860-1865
pubmed: 32451271
Ann Epidemiol. 2006 Nov;16(11):834-41
pubmed: 16843678
Resuscitation. 2020 Aug;153:45-55
pubmed: 32525022
Resuscitation. 2005 Sep;66(3):271-83
pubmed: 16129543

Auteurs

Pedram Sultanian (P)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Peter Lundgren (P)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Anneli Strömsöe (A)

Centre for Clinical Research Dalarna, Uppsala University, S-79182 Falun, Sweden.

Solveig Aune (S)

Unit for Health Care Coordination, Head Office, Region Västra Götaland, Sweden.

Göran Bergström (G)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Eva Hagberg (E)

Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Physiology, Gothenburg, Sweden.

Jacob Hollenberg (J)

Department of Medicine, Centre for Resuscitation Science, Karolinska Institutet, Solna, Sweden.

Jonny Lindqvist (J)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Therese Djärv (T)

Department of Medicine, Centre for Resuscitation Science, Karolinska Institutet, Solna, Sweden.

Albert Castelheim (A)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Anna Thorén (A)

Department of Medicine, Centre for Resuscitation Science, Karolinska Institutet, Solna, Sweden.

Fredrik Hessulf (F)

Department of Anesthesiology and Intensive Care Medicine, Halland Hospital, Halmstad, Sweden.

Leif Svensson (L)

Department of Medicine, Centre for Resuscitation Science, Karolinska Institutet, Solna, Sweden.

Andreas Claesson (A)

Department of Medicine, Centre for Resuscitation Science, Karolinska Institutet, Solna, Sweden.

Hans Friberg (H)

Lund University, Skane University Hospital, Department of Clinical Sciences, Anesthesia & Intensive Care, Malmö, Sweden.

Per Nordberg (P)

Department of Medicine, Centre for Resuscitation Science, Karolinska Institutet, Solna, Sweden.

Elmir Omerovic (E)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Annika Rosengren (A)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Johan Herlitz (J)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Araz Rawshani (A)

University of Gothenburg, Institute of Medicine, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH